Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
16 April 2024
|
|
m 17:29 | Non-degenerate nucleotides per response element 2 changes history +606 [Marshallsumter (2×)] | |||
| m |
|
17:29 (cur | prev) +201 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:14 (cur | prev) +405 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
15:06 | Trismus 3 changes history +1,038 [M. Arsalan Bashir (3×)] | |||
|
|
15:06 (cur | prev) 0 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
|
15:00 (cur | prev) +223 M. Arsalan Bashir talk contribs | ||||
|
|
13:30 (cur | prev) +815 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
|
05:50 | User:Edzelco 2 changes history +33 [Edzelco (2×)] | |||
|
|
05:50 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
05:28 (cur | prev) +15 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 05:50 | Capivasertib diffhist +34,175 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...") | ||||
| N 05:27 | Iptacopan diffhist +33,311 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...") | ||||
| 01:37 | Birch triterpenes diffhist +1,569 Rafael Garcia talk contribs | ||||
15 April 2024
|
|
m 20:06 | Non-degenerate nucleotides per response element 2 changes history +1,954 [Marshallsumter (2×)] | |||
| m |
|
20:06 (cur | prev) +875 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:42 (cur | prev) +1,079 Marshallsumter talk contribs | |||
| 18:43 | Hand contracture diffhist −11 Dj talk contribs | ||||
| 07:25 | User:Edzelco diffhist +16 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 07:24 | Vutrisiran diffhist +17,228 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...") | ||||
14 April 2024
|
|
m 20:07 | Non-degenerate nucleotides per response element 3 changes history +2,087 [Marshallsumter (3×)] | |||
| m |
|
20:07 (cur | prev) +100 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
17:58 (cur | prev) +512 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:09 (cur | prev) +1,475 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:41 | Somatic symptom disorder diffhist +992 Badgettrg talk contribs (→Overview) | ||||
| 14:19 | Systematic review diffhist +554 Badgettrg talk contribs (→Meta-narrative reviews) | ||||